Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.
Viking Therapeutics: Panic Creates Opportunity
Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstrated 12.2% weight loss in 13 weeks, with progressive results and potential for further improvement with longer dosing periods. Concerns over high discontinuation and GI side effects are noted, but these issues are manageable and expected to be addressed in Phase 3 studies.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics: What's Happening With VKTX Stock?
Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.
Viking Therapeutics shares tumble after obesity drug trial disappoints
Shares in Viking Therapeutics (NASDAQ:VKTX) ended a bloody session 42% lower after the US biotech released trial data on its experimental obesity pill that underwhelmed investors. The phase two results showed patients lost up to 12.2 % of body weight after three months on the treatment, VK2735.
Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data
Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.
Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
Viking Therapeutics (VKTX) shares cratered nearly 45% Tuesday when the biopharma firm reported study of its experimental weight-loss pill raised concerns about side effects.
Viking Therapeutics shares plunge on weight loss trial tolerability concerns
Viking Therapeutics (NASDAQ:VKTX) shares tumbled 43% on Tuesday following the release of data from its Phase 2a Venture Oral weight loss trial showing strong efficacy but raised tolerability concerns. The study showed that participants taking VK-2735 achieved placebo-adjusted weight losses of approximately 7.5% at 60 mg, 10% at 90 mg, and 11% at 120 mg over 13 weeks.
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% on Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. While the weight loss caused by Viking's pill was roughly comparable to that of other oral drugs, the side effects and discontinuation rates appeared to rattle Wall Street.
Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against leaders Eli Lilly and Novo Nordisk, as recent results show solid progress. Strong liquidity position provides a reasonable cash runway through 2027, supporting R&D initiatives and upcoming key clinical data releases.
